Why the study?
Does lipid-altering therapy prevent or treat atrial fibrillation?
Does lipid-altering therapy prevent or treat atrial fibrillation?
Lipid-altering therapies such as statins and fish oils may offer antiarrhythmic benefits for recent-onset or post-operative atrial fibrillation, likely mediated by their anti-inflammatory properties.
Answers are grounded in this paper and cite their sources.
May merit consideration in post-operative or recent-onset AF; leaves open benefit in persistent AF and requires prospective trials.
Atrial fibrillation (AF) is a common cardiac arrhythmia with significant morbidity and public health cost. Because of limitations of efficacy and safety of conventional antiarrhythmic agents, alternative therapies for AF are needed. The potential antiarrhythmic properties of lipid-altering therapy, including the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and fish oils, are increasingly recognized, particularly in light of their potential anti-inflammatory properties. This review examines the known effects of lipid-altering therapy on atrial arrhythmias in both experimental and clinical settings. Inflammatory states, such as post-cardiac surgery and AF of recent onset, show promise as targets. In contrast, lipid-lowering therapy is less likely to affect longstanding persistent AF. Current recommendations for the use of lipid-altering therapy for prevention and treatment of AF are summarized.
No takes yet. Share an insight, caveat, or question.
Bachmann et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: